SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio reported Q1 2026 revenue of $194.5M (beat $178.6M consensus)…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed May 7, 2026 at 16:01 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed May 7, 2026 at 16:01 ET

BridgeBio reported Q1 2026 revenue of $194.5M (beat $178.6M consensus) driven by $180.6M in Attruby sales, but EPS of -$0.84 missed the -$0.62 consensus. The company announced a $500M buyback and highlighted strong pipeline progress with upcoming NDAs. Mixed results as strong commercial execution is offset by higher costs and EPS miss.

  • Q1 2026 revenue $194.5M, +66.8% YoY, beat $178.6M consensus
  • Attruby U.S. net product revenue $180.6M vs $36.7M YoY
  • GAAP EPS -$0.84 vs consensus -$0.62 (miss of -35.5%)
  • Cash, cash equivalents and marketable securities $940.2M, up from $587.5M at Dec 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access